Stock VYNE VYNE THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-09 pm EDT 		5-day change 1st Jan Change
1.96 USD 0.00% Intraday chart for VYNE Therapeutics Inc. +8.29% -15.88%
02:00pm VYNE Therapeutics Inc. Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development CI
Jul. 01 VYNE Therapeutics Inc.(NasdaqCM:VYNE) added to Russell 3000E Index CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development
AQ
VYNE Therapeutics Inc. Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development
CI
VYNE Therapeutics Inc.(NasdaqCM:VYNE) added to Russell 3000E Index
CI
VYNE Therapeutics Inc.(NasdaqCM:VYNE) added to Russell Microcap Index
CI
VYNE Therapeutics Inc.(NasdaqCM:VYNE) added to Russell Microcap Value Index
CI
VYNE Therapeutics Inc.(NasdaqCM:VYNE) added to Russell 3000E Value Index
CI
VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum
AQ
Arvinas, Inc. Appoints Andrew Saik as Chief Financial Officer
CI
Arvinas, Inc. Appoints Andrew Saik as Treasurer
CI
VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202
AQ
Vyne Therapeutics Announces Dosing of First Participants in Phase 1A Trial of Novel Bd2-Selective Bet Inhibitor Vyn202
CI
Top Premarket Gainers
MT
VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201
AQ
VYNE Therapeutics Inc. Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201
CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q1 Revenue $98,000
MT
VYNE Reports First Quarter 2024 Financial Results and Provides Business Update
AQ
VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
VYNE Therapeutics Says US FDA Clears its Investigational New Drug Application for Potential Autoimmune Treatment
MT
VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor
AQ
Vyne Therapeutics Announces FDA Clearance of IND Application for Vyn202, A Novel Bd2-Selective Bet Inhibitor
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VYNE Stock
  4. News VYNE Therapeutics Inc.